CC
UTMD icon

Centiva Capital’s Utah Medical Products UTMD Stock Holding History

Centiva Capital’s Portfolio UTMD Stock Details UTMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3,526
Closed -$251K – 2522
2024
Q1 		$251K Buy
+3,526
New +$264K 0.01% 1349

Other funds holding UTMD

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.58B AUM 51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Centiva Capital's UTMD Position: Q2 2024 in Review

Centiva Capital sold out of Utah Medical Products (UTMD) in Q2 2024, closing a stake of 3,526 shares — an estimated $251K sold.

Centiva Capital first reported a position in UTMD in Q1 2024 and held it in 1 quarter. The position peaked at $251K in Q1 2024. 101 funds tracked by Wall St. Rank hold UTMD as of Q2 2024.

  • Centiva Capital reported no remaining Utah Medical Products position as of Q2 2024 after selling out during the quarter.
  • Centiva Capital sold 3,526 Utah Medical Products shares in Q2 2024, an estimated $251K.
  • Centiva Capital first reported a position in Utah Medical Products in Q1 2024 and held it in 1 quarter.
  • Centiva Capital's Utah Medical Products position peaked at $251K in Q1 2024.
  • 101 funds tracked by Wall St. Rank held Utah Medical Products as of Q2 2024.

Based on Centiva Capital's 13F filing for Q2 2024, filed 14 Aug 2024.